Phumlani has a drug resistant form of tuberculosis (TB). His story demonstrates why increased access to new TB drugs is vital. Phumlani is undergoing treatment at MSF's Clinic in Swaziland. Here he discusses the challenges of the medication, including the often toxic side effects, and his hopes for a life without TB. Bedaquiline and delamanid, are the first new tuberculosis drugs in almost 50 years. Along with being more effective, they have fewer side effects. In October 2016, it was estimated that, globally, only 5,738 patients have been able to access bedaquiline, and 405 patients have had access to delamanid.